The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 05, 2022
Filed:
May. 05, 2017
Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;
Université Paul Sabatier Toulouse Iii, Toulouse, FR;
Centre Hospitalier Universitaire DE Toulouse, Toulouse, FR;
Jean-Emmanuel Sarry, Toulouse, FR;
Christian Recher, Toulouse, FR;
Fabienne De Toni-Costes, Toulouse, FR;
Nesrine Aroua, Toulouse, FR;
INSERM, Paris, FR;
UNIVERSITE PAUL SABATIER TOULOUSE III, Toulouse, FR;
CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE, Toulouse, FR;
Abstract
The present invention relates to pharmaceutical compositions for use in the treatment of chemoresistant acute myeloid leukemia (AML). The inventors have established a powerful preclinical model to screen in vivo responses to conventional genotoxics and to mimic the chemoresistance and minimal residual disease as observed in AML patients after chemotherapy. The inventors showed that cytarabine-resistance mechanism involves the CD39-dependent crosstalk between energetic niche and AML mitochondrial functions through CD39-P2Y13-cAMP-PKA signaling axis. In particular, the present invention relates to an inhibitor of the CD39-P2Y13-cAMP-PKA signaling axis for use in a method of treating chemoresistant acute myeloid leukemia (AML) in a patient in need thereof comprising administering to the patient a therapeutically effective amount of said inhibitor.